The longitudinal association between inflammation and incident depressive symptoms in men: The effects of hs-CRP are independent of abdominal obesity and metabolic disturbances

Obesity indices are predictive of elevated C‐reactive protein in long‐haul truck drivers

“…The mean CRP concentration for our cohort of drivers (8.825 ± 9.962 mg/L), was considerably higher than the mean CRP concentrations reported for a similar cohort from the 2009 to 2010 NHANES (3.158 ± 6.990 mg/L, P < 0.001) and consistently higher than most studies that have assessed CRP in various populations [Aronson et al, ; Vidigal et al, ; Camelo et al, ; Tully et al, ]. Similar to Aronson et al, [], levels of CRP suggesting a source of infection or inflammation (>10 mg/L), were most common in individuals with the highest levels of obesity.…”

Association between body size, weight change and depression: systematic review and meta-analysis

“…We assessed the 12 cohort studies and 41 cross-sectional studies that were included in the meta-analysis for BMI categories with a reference BMI of 18.5–22.9, waist circumference (men >102 cm, women >88 cm), weight change and depression. The majority of the studies included in the meta-analysis were found to be of ‘high quality’; however, two cohort studies 5,18 and seven cross-sectional studies 25–28,47,48,51 contained more than two items assessed as ‘low quality’ (online Tables DS5 and DS6).…”

Serum C‐reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice

“…The attention focused on CRP reflects a strong correlation between elevated plasma levels of CRP and the risk of future atherothrombotic events (Chandrashekara, ; Wilson et al, ), including stroke (Elkind et al, ; Idicula et al, ), coronary events (Christiansen, ; Shah et al, ; Shrivastava et al, ), and peripheral arterial disease (Gupta et al, ; Inoue et al, ). Current knowledge suggests that serum hs‐CRP could be useful to estimate the risk of plaque rupture (De Rosa et al, ; Hong et al, ) and the vulnerability of the atheromatous lesion (Libby, ; Zhong et al, ). In contrast, none of the other systemic markers of inflammation, such as upstream cytokine mediators, sensitive acute‐phase proteins, negative acute‐phase proteins, or cruder multifactorial measures, have such robust and desirable characteristics (Marks & Neill, ; Shrivastava et al, ). Recent studies have shown that plasma CRP concentrations predict the risk of the metabolic syndrome because components of the metabolic syndrome (i.e., central obesity, hypertension, low plasma concentrations of high‐density lipoprotein (HDL), increased plasma triglyceride concentrations, and increased concentrations of blood glucose) correlate with increased plasma CRP concentrations (Hoogeveen et al, ; Shrivastava et al, ; Tully et al, ). Current studies suggested that exercise, weight loss, smoking cessation, diet, and diabetes control also reduce serum CRP levels (Church et al, ). Therefore, CRP levels could be used as an inflammation fitness score to assess improvement of CVD.…”

“…It is noteworthy that a prospective study based on serum hs‐CRP demonstrated that women with metabolic syndrome were at greater risk for cardiovascular events (Devaraj, Singh, & Jialal, ). Several epidemiological studies have concluded that obesity with metabolic syndrome seems to be associated with higher levels of CRP and probably increase CVD risk (Tully et al, ). From these findings, serum hs‐CRP was shown to be the most significant predictor of the risk of cardiovascular events in future (J. Kaur, ; Naik, Balaji, Ganjayi, & Reddy, ).…”